# Use of Hydrogen Sulphide Donor (N-acetyl Cysteine) in Cases With Acute Ischemic Stroke

Study · id `cardio:ct-nct07749287` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07749287](<https://clinicaltrials.gov/study/NCT07749287>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07749287

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.

## Technical summary

Registry record NCT07749287. Randomized; double masking; primary purpose treatment. Start 2021-06-01 (actual); primary completion 2023-01-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 121 participants (enrolled count; ClinicalTrials.gov record NCT07749287, source copy `cardio:ctgov-nct07749287-2026-08-06`, retrieved 2026-10-26)
- Started: 2021-06-01 (actual) (ClinicalTrials.gov record NCT07749287, source copy `cardio:ctgov-nct07749287-2026-08-06`, retrieved 2026-10-26)
- Primary completion: 2023-01-01 (actual) (ClinicalTrials.gov record NCT07749287, source copy `cardio:ctgov-nct07749287-2026-08-06`, retrieved 2026-10-26)
- Completion: 2024-03-01 (actual) (ClinicalTrials.gov record NCT07749287, source copy `cardio:ctgov-nct07749287-2026-08-06`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT07749287, source copy `cardio:ctgov-nct07749287-2026-08-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07749287-2026-08-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Use of Hydrogen Sulphide Donor (N-acetyl Cysteine) in Cases With Acute Ischemic Stroke
- Acronym: NAC - H2S
- Condition: Ischemic Cerebral Infarction
- Intervention (Drug): N Acetyl cysteine 600mg
- Intervention (Drug): Normal (0.9%) saline
- Lead sponsor: Helwan University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Helwan University (`cardio:org-helwan-university`)

## Provenance

Content hash: 5e77fb337204b265bafb4e21b3bc56a1ed9d9a0c6ae14bb4d5db9d79092a0911
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
